15/10/02说明:此前论坛服务器频繁出错,现已更换服务器。今后论坛继续数据库备份,不备份上传附件。

肝胆相照论坛

 

 

肝胆相照论坛 论坛 学术讨论& HBV English TherVacB –治疗乙型肝炎的治疗性疫苗 欧盟委员会与Ther ...
查看: 627|回复: 2
go

TherVacB –治疗乙型肝炎的治疗性疫苗 欧盟委员会与TherVacB联 [复制链接]

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

1
发表于 2020-8-9 19:20 |只看该作者 |倒序浏览 |打印
TherVacB – A THERAPEUTIC VACCINE TO CURE HEPATITIS B
European Commission and TherVacB join forces

The role of viral hepatitis as a public health threat has long been underestimated. Only very recently, the United Nations in their “2030 Agenda for Sustainable Development” called for international action to combat viral hepatitis and reduce the disease burden. The major killer is the hepatitis B virus (HBV) causing liver cirrhosis and liver cancer, and worldwide 880,000 humans die each year from the consequences of an HBV infection.

A prophylactic vaccine is available to prevent HBV infection, but more than 3% of the world’s population (about 260 million humans) are chronically infected and do not profit from that vaccine anymore. For those suffering from chronic hepatitis B, until today no curative treatment option exists.

The European Commission therefore selected the project TherVacB led by Helmholtz Zentrum München for a five-year funding within the Horizon 2020 program.
A consortium of leading virologists, immunologists and physicians specialized in treating viral hepatitis, will use a newly designed therapeutic vaccine, TherVacB, as an immunotherapy to cure HBV. TherVacB will be evaluated in a three-year clinical trial starting in 2021 conducted in Europe and in Africa. Integration of a partner site in Tanzania shall help building local capacities for diagnosing and treating hepatitis B and support an important goal of the consortium – to raise awareness for hepatitis B.

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

2
发表于 2020-8-9 19:20 |只看该作者
TherVacB –治疗乙型肝炎的治疗性疫苗
欧盟委员会与TherVacB联手

长期以来,人们一直低估了病毒性肝炎作为公共卫生威胁的作用。直到最近,联合国才在其“ 2030年可持续发展议程”中呼吁采取国际行动,与病毒性肝炎作斗争并减轻疾病负担。主要杀手是导致肝硬化和肝癌的乙肝病毒(HBV),全世界每年有880,000人死于HBV感染的后果。

预防性疫苗可以预防HBV感染,但是世界人口中有3%以上(约2.6亿人)被慢性感染,不再从该疫苗中受益。对于那些患有慢性乙型肝炎的患者,直到今天还没有治愈的选择。

因此,欧盟委员会选择了由Helmholtz ZentrumMünchen领导的TherVacB项目,作为“地平线2020”计划中的五年资金。
由专门从事病毒性肝炎治疗的领先病毒学家,免疫学家和医师组成的联盟将使用新设计的治疗性疫苗TherVacB作为治疗HBV的免疫疗法。 TherVacB将在2021年在欧洲和非洲进行的一项为期三年的临床试验中进行评估。坦桑尼亚合作伙伴地点的整合将有助于建立当地诊断和治疗乙型肝炎的能力,并支持该联盟的重要目标-提高对乙型肝炎的认识。

Rank: 8Rank: 8

现金
62111 元 
精华
26 
帖子
30437 
注册时间
2009-10-5 
最后登录
2022-12-28 

才高八斗

3
发表于 2020-8-9 19:20 |只看该作者
‹ 上一主题|下一主题
你需要登录后才可以回帖 登录 | 注册

肝胆相照论坛

GMT+8, 2024-10-4 06:43 , Processed in 0.015677 second(s), 16 queries , Gzip On.

Powered by Discuz! X1.5

© 2001-2010 Comsenz Inc.